GlassScriptPhysician profile
Jason P Schott
NPI 1942628748
$24,969.90
in general payments reported to CMS, 2019-2025
25 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.55 · 2020: $37.45 · 2021: $18K · 2022: $3,427 · 2023: $1,938 · 2024: $954 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486 · Education: $4.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.86 |
| Education | $4.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,523.39 | 2021-2024 | Corevalve Evolut R, Onyx Frontier, Na |
| Abbott Laboratories | $5,041.79 | 2021-2024 | Amplatzer Talisman, Cardiomems |
| Edwards Lifesciences Corporation | $2,776.45 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $1,303.97 | 2019-2025 | Avvigo Guidance System, Watchman Flx, General - Vascular Intervention |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $441.03 | 2022-2025 | Lifevest |
| Abiomed | $345.41 | 2022-2024 | Impella |
| Cardiva Medical, INC. | $259.23 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Savvywire, Optowire |
| E.R. Squibb & Sons, L.L.C. | $185.15 | 2024-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $175.66 | 2023 | Xarelto |
| Inari Medical, INC. | $171.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $156.74 | 2023-2025 | |
| Penumbra, INC. | $97.36 | 2023 | Indigo System |
| Novo Nordisk INC | $82.59 | 2025 | Wegovy |
| Pfizer INC. | $75.29 | 2024-2025 | |
| Amgen INC. | $72.62 | 2024-2025 | Repatha, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.95 | 2024-2025 | Keytruda, Verquvo |
| Sanofi-Aventis U.S. LLC | $42.06 | 2023 | |
| Zoll Circulation INC | $37.57 | 2023-2024 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Terumo Medical Corporation | $26.05 | 2023 | Metacross Otw, Glidewire, Heartrail |
| Acist Medical Systems, INC. | $24.99 | 2022-2023 | |
| Philips North America LLC | $24.92 | 2024 | (Bq9) Coronary Ivus |
| United Therapeutics Corporation | $18.51 | 2025 | Tyvaso |
| Biotronik INC. | $17.81 | 2023 | Orsiro Mission, Recross, Pk Papyrus |
| Elutia, INC. | $14.48 | 2023 | |
| Teleflex LLC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Schott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.